Biotest
Peter Janssen has been a member of the Board of Management of Biotest AG since 2022 and is leading its Commercial and Industrial Operations. He was previously Executive VP of Prothya Netherlands and CEO of Prothya Belgium. Mr. Janssen also worked 14 years for Pfizer and 5 years for its animal health spin-off Zoetis where he performed various transformational, strategic and global operational roles with increasing responsibilities.
Peter started his career as an assistant Professor at the University of Leuven in Belgium, was a reserve officer at the Belgian Air Force and worked in the semiconductor division of world-leading industrial gases company Air Products in Pennsylvania, US. He holds a Master of Science degree in Electro-Mechanical Engineering, a Master degree in Applied Economics and Business Degree from INSEAD, France. Peter Janssen was born in 1966.
This person is not in the org chart
This person is not in any offices
Biotest
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.